Aneurysmal Subarachnoid Hemorrhage (aSAH) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Aneurysmal Subarachnoid Hemorrhage (aSAH) Emerging Therapy and TPP Insights

Thelansis’s “Aneurysmal Subarachnoid Hemorrhage (aSAH) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Overview

Aneurysmal subarachnoid hemorrhage (aSAH) is a catastrophic neurological emergency caused by intracranial aneurysm rupture, discharging arterial blood into the subarachnoid space and driving acute intracranial hypertension. Presentation is defined by a sudden thunderclap headache, meningism, photophobia, and rapid altered consciousness. Non-contrast cranial CT provides definitive initial screening, backed by lumbar puncture for xanthochromia if neuroimaging is negative. Severity is graded clinically via Hunt-Hess or WFNS metrics. Frontline intervention requires microvascular surgical clipping or endovascular coiling to secure the culprit lesion, preferably within 24 hours to prevent rebleeding. Managing secondary complications centers on preventing delayed cerebral ischemia (DCI)—a multifactorial injury cascade involving microcirculatory dysfunction and cortical spreading depolarizations. While early enteral nimodipine remains the baseline standard of care to optimize functional outcomes, management has completely moved past outdated, prophylactic “Triple-H” therapy. Instead, neuro-ICU protocols enforce targeted euvolemia, strict normothermia, and avoidance of hypotension. Refractory ischemia is monitored using transcranial Doppler (TCD) or perfusion imaging, prompting rescue-induced hypertension or endovascular angioplasty. Furthermore, standard care avoids routine phenytoin-based seizure prophylaxis, replacing it with continuous EEG to track subclinical non-convulsive status epilepticus. Long-term recovery demands structured neuropsychological support and coordinated neuro-rehabilitation.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Aneurysmal Subarachnoid Hemorrhage (aSAH) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026